ACC/AHA/HFSA Focused Update Developed in Collaboration With the American College of Chest Physi- cians and International Society for Heart and Lung Transplantation ACC/AHA Task Force Members, see page e287 WRITING COMMITTEE MEMBERS* Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, Chair Mariell Jessup, MD, FACC, FAHA, FESC, Vice Chair Biykem Bozkurt, MD, PhD, FACC, FAHA Javed Butler, MD, MBA, MPH, FACC, FAHA Donald E. Casey, Jr, MD, MPH, MBA, FACC Monica M. Colvin, MD, FAHA Mark H. Drazner, MD, MSc, FACC, FAHA Gerasimos Filippatos, MD, FESC Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Michael M. Givertz, MD, FACC, FHFSA Steven M. Hollenberg, MD, FACC# JoAnn Lindenfeld, MD, FACC, FAHA, FHFSA Frederick A. Masoudi, MD, MSPH, FACC** Patrick E. McBride, MD, MPH, FACC Pamela N. Peterson, MD, FACC Lynne Warner Stevenson, MD, FACC Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Key Words: AHA Scientific Statements angioedema angiotensin-converting enzyme inhibitors angiotensin receptor blockers angiotensin receptor- neprilysin inhibitor beta blockers focused update heart failure ivabradine natriuretic peptides 2016 by the American College of Cardiology Foundation, the American Heart Association, Inc., and the Heart Failure Society of America. 